Nicole Brighi1, Giuseppe Lamberti2, Ilaria Maggio2, Lisa Manuzzi2, Claudio Ricci3, Riccardo Casadei3, Donatella Santini4, Cristina Mosconi5, Andrea Lisotti6, Valentina Ambrosini7, Maria Abbondanza Pantaleo2, Davide Campana3. 1. NET Team Bologna ENETS Center of Excellence, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy; Interdepartmental Center of Cancer Research "Giorgio Prodi", S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy. Electronic address: nicolebrighi@hotmail.com. 2. Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy. 3. NET Team Bologna ENETS Center of Excellence, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy. 4. NET Team Bologna ENETS Center of Excellence, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy; Department of Diagnostic and Prevention Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy. 5. NET Team Bologna ENETS Center of Excellence, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy; Radiology Unit, Department of Digestive Disease and Internal Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy. 6. Department of Medical and Surgical Science, Gastroenterology Unit, Hospital of Imola, Alma Mater Studiorum University of Bologna, Imola, Italy. 7. NET Team Bologna ENETS Center of Excellence, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy; Nuclear Medicine, Department of Experimental Diagnostic and Specialized Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Abstract
BACKGROUND: Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs: an increased incidence has been reported in somatostatin analogs-treated acromegalic patients, but studies on patients with neuroendocrine neoplasms are lacking. AIMS: To evaluate biliary stone disease incidence and associated factors in a large series of patients treated with somatostatin analogs for neuroendocrine neoplasms. METHODS: A prospectively-collected database of patients with a diagnosis of neuroendocrine neoplasms of any grade and site, treated with somatostatin analogs at our Institution between 1995 and 2017, was retrospectively analyzed. Patients' demographics and disease characteristics were analyzed to evaluate the incidence and the factors related to biliary stone disease. RESULTS: Three-hundred patients were included; 101 (33.7%) patients underwent cholecystectomy before starting somatostatin analogs. Among 164 patients with gallbladder in situ and no history of stone disease, 60 (36.6%) developed gallstones after a mean of 36.7 months (range 1-239) from treatment start with a mean yearly incidence of 8.73%. Previous cholecystectomy was associated with a lower rate of development of gallstones (p < 0.001) or related complications (p = 0.017). CONCLUSION: We observed a high incidence of biliary stone disease in patients treated with somatostatin analogs-treated for neuroendocrine neoplams. Previous cholecystectomy was the only factor associated with a lower occurrence of biliary stone disease.
BACKGROUND:Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs: an increased incidence has been reported in somatostatin analogs-treated acromegalicpatients, but studies on patients with neuroendocrine neoplasms are lacking. AIMS: To evaluate biliary stone disease incidence and associated factors in a large series of patients treated with somatostatin analogs for neuroendocrine neoplasms. METHODS: A prospectively-collected database of patients with a diagnosis of neuroendocrine neoplasms of any grade and site, treated with somatostatin analogs at our Institution between 1995 and 2017, was retrospectively analyzed. Patients' demographics and disease characteristics were analyzed to evaluate the incidence and the factors related to biliary stone disease. RESULTS: Three-hundred patients were included; 101 (33.7%) patients underwent cholecystectomy before starting somatostatin analogs. Among 164 patients with gallbladder in situ and no history of stone disease, 60 (36.6%) developed gallstones after a mean of 36.7 months (range 1-239) from treatment start with a mean yearly incidence of 8.73%. Previous cholecystectomy was associated with a lower rate of development of gallstones (p < 0.001) or related complications (p = 0.017). CONCLUSION: We observed a high incidence of biliary stone disease in patients treated with somatostatin analogs-treated for neuroendocrine neoplams. Previous cholecystectomy was the only factor associated with a lower occurrence of biliary stone disease.
Authors: Nicole Brighi; Francesco Panzuto; Roberta Modica; Fabio Gelsomino; Manuela Albertelli; Sara Pusceddu; Sara Massironi; Giuseppe Lamberti; Maria Rinzivillo; Antongiulio Faggiano; Andrea Spallanzani; Diego Ferone; Natalie Prinzi; Roberta Elisa Rossi; Bruno Annibale; Anna Maria Colao; Davide Campana Journal: Oncologist Date: 2019-11-06
Authors: Sophie E Aapkes; Robbert J de Haas; Lucas H P Bernts; Charles J Blijdorp; Sosha E I Dekker; Maatje D A van Gastel; Esther Meijer; Abigail Veldman; Joost P H Drenth; Ron T Gansevoort Journal: Drugs R D Date: 2021-03-29
Authors: N Prencipe; C Bona; D Cuboni; M Parasiliti-Caprino; A M Berton; L M Fenoglio; V Gasco; E Ghigo; S Grottoli Journal: Pituitary Date: 2020-11-09 Impact factor: 4.107